BioNTech (NASDAQ:BNTX) Earns "Buy" Rating from Berenberg Bank

Key Points

• Berenberg Bank reaffirmed a "Buy" rating on BioNTech, and analysts overall give the stock a consensus rating of "Moderate Buy" with a consensus price target of $133.13 (breakdown: 1 Strong Buy, 12 Buy, 4 Hold, 1 Sell).
• BioNTech reported ($0.39) EPS and $1.06 billion revenue for the last quarter, with negative net margin and return on equity, and analysts expect about -3.88 EPS for the current fiscal year.
• The stock trades around $98 (opened $98.09) with a market cap of $24.8 billion and a 52-week range of $79.52 to $124.00.

BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its "buy" rating reaffirmed by Berenberg Bank in a note issued to investors on Monday,MarketScreener reports.

A number of other brokerages also recently commented on BNTX. Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a research note on Wednesday. BMO Capital Markets reduced their target price on shares of BioNTech from $143.00 to $128.00 and set an "outperform" rating for the company in a report on Wednesday, March 11th. Jefferies Financial Group reissued a "buy" rating on shares of BioNTech in a report on Wednesday, March 25th. Wall Street Zen cut shares of BioNTech from a "hold" rating to a "sell" rating in a report on Saturday, March 14th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $171.00 target price on shares of BioNTech in a research report on Wednesday, March 11th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $133.13.

BioNTech Stock Performance

NASDAQ:BNTX opened at $98.09 on Monday. The company has a fifty day simple moving average of $98.81 and a two-hundred day simple moving average of $101.05. The company has a market cap of $24.80 billion, a price-to-earnings ratio of -18.67 and a beta of 1.58. The company has a quick ratio of 7.49, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. BioNTech has a 52 week low of $79.52 and a 52 week high of $124.00.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The business had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%. As a group, equities analysts anticipate that BioNTech will post -3.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently bought and sold shares of the stock. Larson Financial Group LLC raised its stake in shares of BioNTech by 86.4% in the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company's stock valued at $26,000 after acquiring an additional 127 shares during the period. Kennedy Capital Management LLC raised its stake in shares of BioNTech by 0.6% in the 4th quarter. Kennedy Capital Management LLC now owns 21,065 shares of the company's stock valued at $2,005,000 after acquiring an additional 134 shares during the period. Probity Advisors Inc. raised its stake in shares of BioNTech by 5.7% in the 3rd quarter. Probity Advisors Inc. now owns 2,506 shares of the company's stock valued at $247,000 after acquiring an additional 135 shares during the period. Mackenzie Financial Corp raised its stake in shares of BioNTech by 4.0% in the 3rd quarter. Mackenzie Financial Corp now owns 4,290 shares of the company's stock valued at $418,000 after acquiring an additional 165 shares during the period. Finally, GAMMA Investing LLC raised its stake in shares of BioNTech by 40.8% in the 3rd quarter. GAMMA Investing LLC now owns 784 shares of the company's stock valued at $77,000 after acquiring an additional 227 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.